15.31
15.31 (0%)
As of Feb 16, 2024
Icosavax, Inc. [ICVX]
Source:
Company Overview
We are a biopharmaceutical company leveraging our innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Our VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which we believe will induce broad, robust, and durable protection against the specific viruses targeted.
| Country | United States |
| Headquarters | seattle, washington |
| Phone Number | (206) 737-0085 |
| Industry | |
| CEO | Adam Simpson |
| Website | www.icosavax.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-25.3 |
| Net Income | $-22 |
| Net Cash | $3.3 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -9% |
| Profit as % of Stockholder Equity | -9.5% |
Management Effectiveness
| Return on Equity | -9.5% |
| Return on Assets | -8.8% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $251.3 |
| Total Liabilities | $18.9 |
| Operating Cash Flow | $-59.8 |
| Investing Cash Flow | $-4.8 |
| Financing Cash Flow | $68 |
